Loading organizations...
§ Private Profile · 2326 Walsh Ave Santa Clara, California 95051, USA
Clinical-stage medical technology company with FDA Breakthrough Device Designation for splanchnic nerve ablation for heart failure (HFpEF).
Axon Therapies is a clinical-stage medical technology company based in Santa Clara, California, that develops minimally invasive, implant-free catheter-based treatments for cardiovascular conditions. The company's flagship technology utilizes splanchnic nerve ablation to restore blood volume balance and reduce pressure in adult patients suffering from heart failure with preserved ejection fraction, requiring an outpatient procedure that takes under one hour. The ablation system has officially received Breakthrough Device Designation from the United States Food and Drug Administration and presented positive early clinical data from its ongoing REBALANCE-HF trial in late 2023. Operating as a pre-revenue venture-backed entity, the firm emerged from the medical device incubator Coridea and has secured financial backing from institutional investors including Action Potential Venture Capital. Axon Therapies was founded in 2014 by medical device entrepreneurs Howard Levin and Mark Gelfand.
Axon Therapies has raised $32.0M across 1 funding round.
Axon Therapies has raised $32.0M in total across 1 funding round.
Axon Therapies has raised $32.0M in total across 1 funding round.
Axon Therapies's investors include Earlybird Venture Capital, James Eadie, EQT Life Sciences, Seroba Life Sciences, Andrew ElBardissi, Deerfield Management, KOFA Healthcare.
Axon Therapies is a clinical-stage medical technology company developing the Satera™ Ablation System for Splanchnic Ablation for Volume Management (SAVM), a minimally invasive, implant-free catheter-based procedure to treat heart failure by targeting overactivity in the sympathetic nervous system.[1][2][3][6] It primarily serves cardiology patients with heart failure, including those with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), addressing a root cause of disease progression—volume overload and sympathetic nerve hyperactivity—that current therapies often fail to resolve effectively.[1][3][4][6] The company has raised $42.8M total, including a $32M oversubscribed Series A in September 2025, fueling pivotal trials amid strong early clinical data from studies like REBALANCE-HF showing safety, tolerability, and responder improvements in functional capacity and biomarkers.[3][7]
Axon Therapies was founded in 2014 by MedTech incubator Coridea in Santa Clara, California, emerging from research on splanchnic nerve ablation to manage volume in heart failure patients.[1][3][5] Co-founder Zoar Engelman, PhD, transitioned from Chief Scientific Officer to CEO in September 2025 alongside the Series A raise, bringing deep expertise in the therapy's science.[3] Early milestones include $10.8M in prior funding (last in 2019 from Deerfield Management), 21 patents focused on heart failure devices, and pivotal feasibility studies like REBALANCE-HF, which validated the procedure's safety and efficacy signals in HFpEF patients.[1][2][3][7]
Axon rides the wave of device-based neuromodulation in cardiology, targeting the HFpEF epidemic—where 50% of heart failure cases occur but therapies are scarce—amid rising global incidence driving hospitalizations and deaths.[3][4][6] Timing aligns with maturing catheter tech and post-COVID heart failure surges, bolstered by peer-reviewed evidence from REBALANCE-HF establishing SAVM as a feasible frontline option.[7] Market tailwinds include demand for minimally invasive alternatives to drugs or implants, influencing medtech by validating nerve ablation for volume management and potentially expanding to HFrEF, reshaping treatment paradigms.[1][2][7]
Axon is primed for pivotal trials with fresh $32M capital, positioning SAVM for FDA clearance and commercialization as a breakthrough for underserved HFpEF patients.[3] Neuromodulation trends and expanding HFrEF data could broaden adoption, while partnerships with clinical centers accelerate evidence-building. Expect influence growth through regulatory wins and scale, transforming heart failure care from reactive to causal—echoing its mission to rebalance a deadly disease.
Axon Therapies has raised $32.0M across 1 funding round. Most recently, it raised $32.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $32M Series A | Earlybird Venture Capital, James Eadie | EQT Life Sciences, Seroba Life Sciences, Andrew Elbardissi, Deerfield Management, KOFA Healthcare | Announced |